Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24684821 | 0.91 | AR (0.63) | ARPGR | |
| SCHEMBL26799786 | 0.88 | AR (0.63) | ARPGR | |
| SCHEMBL4024954 | 0.88 | AR (0.76) | AR | |
| SCHEMBL2216099 | 0.85 | AR (0.63) | ARPGR | |
| SCHEMBL4026199 | 0.85 | AR (0.78) | ARPGR | |
| SCHEMBL8172287 | 0.85 | AR (0.56) | ARPGR | |
| SCHEMBL8177485 | 0.85 | AR (0.59) | ARPGR | |
| SCHEMBL8559864 | 0.84 | AR (0.61) | ARPGR | |
| SCHEMBL26799996 | 0.83 | AR (0.54) | AR | |
| SCHEMBL4027208 | 0.82 | AR (0.74) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| WO-2009097996-A1 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINES FOR PRODUCING MEDICAMENTS FOR TREATING METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| EP-0671156-B1 | Process to prepare cosmetic or pharmaceutical compositions containing liposomes | AVENTIS PHARMA SA (FR) | 2001-10-24 | — | — | EP | disclosed |
| US-6162444-A | Cosmetic or pharmaceutical compositions | HOECHST MARION ROUSSEL (FR) | 2000-12-19 | — | — | US | disclosed |
| CN-1049214-C | Phenylimidazolidines, process for their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 2000-02-09 | — | — | CN | disclosed |
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | disclosed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | disclosed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0671156-A1 | Cosmetic or pharmaceutical compositions containing liposomes | ROUSSEL UCLAF (FR) | 1995-09-13 | — | — | EP | disclosed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | disclosed |
| CN-1063102-A | New phenylimidazolidines,, prepare they method, they are as the application of medicine and the pharmaceutical composition that contains them | ROUSSEL UCLAF (FR) | 1992-07-29 | — | — | CN | disclosed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.